Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

PURPOSE BRCA1 or BRCA2 ( BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients with mCRPC associated with a BRCA alteration treated with rucaparib 600 mg twice daily in the phase II TRITON2 study. METHODS We enrolled patients who progressed after one to two lines of next-generation androgen receptor–directed therapy and one taxane-based chemotherapy for mCRPC. Efficacy and safety populations included patients with a deleterious BRCA alteration who received ≥ 1 dose of rucaparib. Key efficacy end points were objective response rate (ORR; per RECIST/Prostate Cancer…

• UD
  U.S. Department of Defense

  Awards: W81XWH-17, W81XWH, W81XWH-17-1-0124
• PC
  Prostate Cancer Foundation

  Award: P30-CA008748
• BS
  Bristol-Myers Squibb
• P
  Pfizer
• A
  AstraZeneca
• S
  Sanofi
• E
  Endocyte
• E
  Exelixis
• CO
  Clovis Oncology
• E
  Eisai
• AP
  Astellas Pharma
• I
  Ipsen
• G
  Genentech
• NC
  National Cancer Institute

  Awards: CA092629, CA008748, P50-CA092629, P30-CA008748
• C
  Cilag
• DP
  DOD Prostate Cancer Research Program

  Award: W81XWH-17-1-0124